Following the success of its Phase 1 project, XCMR has been awarded a $784,502 Phase 2 AFWERX award by the Department of Defense. This funding will further support the development of XCMR’s next-generation personal protective equipment (PPE) for real-time inactivation of airborne biological threats. Building on the proof-of-concept established in Phase 1, this award highlights the significant progress XCMR has made in refining its innovative Far UV-C technology.
The Phase 2 award is a testament to the progress XCMR demonstrated during Phase 1, where its Far UV-C equipped PPE showed potential for real-time pathogen inactivation. The new funding will allow XCMR to refine the design, integrate new features, and optimize performance for real-world use.
Securing an AFWERX Phase 2 award indicates the DoD’s confidence in XCMR’s technology. AFWERX’s support will help accelerate the transition from development to deployment, bringing life-saving PPE closer to being used by healthcare workers, military personnel, and civilians in high-risk environments.
This Phase 2 funding enables XCMR to focus on scaling production, further testing, and ensuring the integration of its Far UV-C technology into PPE designs that are ready for the market. With a duration of 15 months, the project will focus on refining the device’s ability to protect against airborne biological threats in various settings.
XCMR’s Phase 2 AFWERX award marks a significant step forward in the development of next-generation PPE for real-time pathogen inactivation. With continued support from the Department of Defense, XCMR is on track to deliver advanced solutions that address the challenges posed by airborne biological threats and enhance safety for those on the front lines.
